Cargando…
Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis
OBJECTIVE: Recent years have seen new evidence on the efficacy and safety of dual antiplatelet therapy for secondary stroke prevention. We updated a meta-analysis of randomised controlled trials evaluating dual antiplatelet versus monotherapy for patients with acute non-cardioembolic ischaemic strok...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047341/ https://www.ncbi.nlm.nih.gov/pubmed/30022798 http://dx.doi.org/10.1136/svn-2018-000168 |
_version_ | 1783339936120832000 |
---|---|
author | Yang, Yingying Zhou, Mengyuan Zhong, Xi Wang, Yongjun Zhao, Xingquan Liu, Liping Wang, Yilong |
author_facet | Yang, Yingying Zhou, Mengyuan Zhong, Xi Wang, Yongjun Zhao, Xingquan Liu, Liping Wang, Yilong |
author_sort | Yang, Yingying |
collection | PubMed |
description | OBJECTIVE: Recent years have seen new evidence on the efficacy and safety of dual antiplatelet therapy for secondary stroke prevention. We updated a meta-analysis of randomised controlled trials evaluating dual antiplatelet versus monotherapy for patients with acute non-cardioembolic ischaemic stroke (IS) or transient ischaemic attack (TIA). METHODS: We searched PubMed and identified randomised controlled trials evaluating dual antiplatelet versus monotherapy for acute non-cardioembolic IS or TIA within 3 days of ictus up to May 2018. Risk ratio (RR) with 95% CI were calculated using random effects models. Clinical endpoints included stroke recurrence, composite vascular events and major bleeding. RESULTS: 18 randomised controlled trials including 15 515 patients were pooled in the meta-analysis. When compared with monotherapy among patients with acute IS or TIA, dual antiplatelet therapy reduced the risk of stroke recurrence (RR 0.69; 95% CI 0.61 to 0.78; p<0.001) and composite vascular events (RR 0.72; 95% CI 0.64 to 0.80; p<0.001). Dual therapy was associated with a significant increase in the risk of major bleeding (RR 1.77; 95% CI 1.09 to 2.87; p=0.02) when all trial data were combined. However, when all previous trials before the completion of the POINT trial were analysed, dual antiplatelet versus monotherapy was not associated with a significant increase in the risk of major bleeding (RR 1.46; 95% CI 0.77 to 2.75; p=0.25). CONCLUSIONS: Among patients with acute non-cardioembolic IS or TIA within 3 days of ictus, dual antiplatelet therapy was associated with a reduction in stroke recurrence, and composite vascular events, when compared with monotherapy. However, a significant increase in the risk of major bleeding was observed. |
format | Online Article Text |
id | pubmed-6047341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-60473412018-07-18 Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis Yang, Yingying Zhou, Mengyuan Zhong, Xi Wang, Yongjun Zhao, Xingquan Liu, Liping Wang, Yilong Stroke Vasc Neurol Original Article OBJECTIVE: Recent years have seen new evidence on the efficacy and safety of dual antiplatelet therapy for secondary stroke prevention. We updated a meta-analysis of randomised controlled trials evaluating dual antiplatelet versus monotherapy for patients with acute non-cardioembolic ischaemic stroke (IS) or transient ischaemic attack (TIA). METHODS: We searched PubMed and identified randomised controlled trials evaluating dual antiplatelet versus monotherapy for acute non-cardioembolic IS or TIA within 3 days of ictus up to May 2018. Risk ratio (RR) with 95% CI were calculated using random effects models. Clinical endpoints included stroke recurrence, composite vascular events and major bleeding. RESULTS: 18 randomised controlled trials including 15 515 patients were pooled in the meta-analysis. When compared with monotherapy among patients with acute IS or TIA, dual antiplatelet therapy reduced the risk of stroke recurrence (RR 0.69; 95% CI 0.61 to 0.78; p<0.001) and composite vascular events (RR 0.72; 95% CI 0.64 to 0.80; p<0.001). Dual therapy was associated with a significant increase in the risk of major bleeding (RR 1.77; 95% CI 1.09 to 2.87; p=0.02) when all trial data were combined. However, when all previous trials before the completion of the POINT trial were analysed, dual antiplatelet versus monotherapy was not associated with a significant increase in the risk of major bleeding (RR 1.46; 95% CI 0.77 to 2.75; p=0.25). CONCLUSIONS: Among patients with acute non-cardioembolic IS or TIA within 3 days of ictus, dual antiplatelet therapy was associated with a reduction in stroke recurrence, and composite vascular events, when compared with monotherapy. However, a significant increase in the risk of major bleeding was observed. BMJ Publishing Group 2018-06-26 /pmc/articles/PMC6047341/ /pubmed/30022798 http://dx.doi.org/10.1136/svn-2018-000168 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Original Article Yang, Yingying Zhou, Mengyuan Zhong, Xi Wang, Yongjun Zhao, Xingquan Liu, Liping Wang, Yilong Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis |
title | Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis |
title_full | Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis |
title_fullStr | Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis |
title_full_unstemmed | Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis |
title_short | Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis |
title_sort | dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047341/ https://www.ncbi.nlm.nih.gov/pubmed/30022798 http://dx.doi.org/10.1136/svn-2018-000168 |
work_keys_str_mv | AT yangyingying dualversusmonoantiplatelettherapyforacutenoncardioembolicischaemicstrokeortransientischaemicattackasystematicreviewandmetaanalysis AT zhoumengyuan dualversusmonoantiplatelettherapyforacutenoncardioembolicischaemicstrokeortransientischaemicattackasystematicreviewandmetaanalysis AT zhongxi dualversusmonoantiplatelettherapyforacutenoncardioembolicischaemicstrokeortransientischaemicattackasystematicreviewandmetaanalysis AT wangyongjun dualversusmonoantiplatelettherapyforacutenoncardioembolicischaemicstrokeortransientischaemicattackasystematicreviewandmetaanalysis AT zhaoxingquan dualversusmonoantiplatelettherapyforacutenoncardioembolicischaemicstrokeortransientischaemicattackasystematicreviewandmetaanalysis AT liuliping dualversusmonoantiplatelettherapyforacutenoncardioembolicischaemicstrokeortransientischaemicattackasystematicreviewandmetaanalysis AT wangyilong dualversusmonoantiplatelettherapyforacutenoncardioembolicischaemicstrokeortransientischaemicattackasystematicreviewandmetaanalysis |